Abbott Laboratories (ABT) Operating Expenses (2009 - 2026)

Abbott Laboratories has disclosed Operating Expenses across 18 years of filings, most recently posting $9.8 billion for Q1 2026.

• Operating Expenses for Q1 2026 came in at $9.8 billion, up 13.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.4 billion (up 6.3% YoY), and the FY2025 annual result was $36.3 billion, up 3.27% from the prior year.
• Operating Expenses came in at $9.8 billion for Q1 2026 at Abbott Laboratories, up from $9.2 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $9.8 billion in Q1 2026 to a low of $8.2 billion in Q1 2023.
• The 5-year median for Operating Expenses is $8.8 billion (2024), against an average of $8.8 billion.
• Across the five-year window, Operating Expenses slipped 8.29% in 2023 and advanced 13.32% in 2026, its largest moves.
• Abbott Laboratories' Operating Expenses stood at $8.8 billion in 2022, then fell by 3.71% to $8.5 billion in 2023, then gained by 7.11% to $9.1 billion in 2024, then climbed by 1.6% to $9.2 billion in 2025, then rose by 6.64% to $9.8 billion in 2026.
• The last three Operating Expenses figures came in at $9.8 billion (Q1 2026), $9.2 billion (Q4 2025), and $9.3 billion (Q3 2025), per Business Quant data.